Clinerion and O.I.s Partner to Create Oncology Platform
PPD’s AES Acquires Global Site Business from Bioclinica
Tufts Study: Cancer Drugs Now Account for 27% of all New Drug Approvals
Novartis Data Manipulation Spotlights Wider Concerns
Regulatory enforcement actions, policy updates, and new guidelines show that ensuring the reliability of clinical data is an ongoing priority.
Advarra Announces Intent to Acquire Forte
Harbour BioMed Leverages PPD’s Biotech to Develop Innovative Therapeutics
WCG Introduces Velos eResearch eXpress
Improving Information Exchange in Clinical Trials
Executives from across the clinical research enterprise converge to discuss the steps-and technology-needed to strengthen industrywide data sharing.
Workforce Readiness Technology Minimizes Risk in Clinical Trials
Joel B. Selzer, co-founder and CEO, ArcheMedX, Inc., discusses the impact that healthcare technology has on clinical trials, focusing on the development of the company’s workforce readiness platform.
The VA Gets Real on Reform
After years of siloed focus-and slow study start-ups-the U.S. Veterans Affairs agency embarks on implementing its multi-year initiative to bolster clinical research.
No End in Sight to European Debates About Drug Firms’ Influence on Regulators
The two-year inquiry into possible maladministration at the EMA has intensified.
Applied Clinical Trials, September 2019 Issue (PDF)
Click the title above to open the Applied Clinical Trials September 2019 issue in an interactive PDF format.
Sponsors, Regulators Cautious About Risk-Based Oversight of Clinical Trials
FDA and other regulators are responding with support for more flexible monitoring of clinical investigators and review of study records in order to limit study monitoring to certain situations.
Creating Medicines ‘Appropriate for All’
Bristol-Myers Squibb’s cardiovascular development leader discusses the importance of diversifying clinical trials for better patient outcomes.
Taking Care of Site Business
A view of highlights and trends from the September 2019 issue, alongside trends mentioned around site practices during the year.
Proliferation of Rare Disease R&D Necessitating Novel Strategies
Interest in benchmark data on the scope, performance, and economics of rare disease drug development efforts has grown.
How Organizations Can Put Sites First When Implementing New Trial Technology
Organizations that continue to disregard the technological needs of one of the industry’s core audiences run the risk of having their trials ignored.
Alzheimer’s Disease Research Finds New Beginnings
Dr. Daniel Alkon, President & Chief Science Officer at Neurotrope, discusses novel approaches to AD therapy development and why his company chose to target patients with advanced AD for their own.
Evidera and CSS Collaborate in Japan
Jehangir Hospital joins Clinerion’s Patient Network Explorer
IQVIA Launches Patient Portal
Overcoming The Hurdles of Starting up a Biopharmaceutical Company
CEO of eXIthera, Neil Hayward, talks about his experience overcoming the challenges of starting up an emerging biopharmaceutical company, including the challenges of preclinical and early-stage development.
